BriaCell Therapeutics Corp. (NASDAQ:BCTX) Short Interest Down 28.2% in November

BriaCell Therapeutics Corp. (NASDAQ:BCTX) was the recipient of a significant decrease in short interest in the month of November. As of November 15th, there was short interest totalling 534,800 shares, a decrease of 28.2% from the October 31st total of 745,100 shares. Based on an average daily volume of 5,020,000 shares, the days-to-cover ratio is currently 0.1 days. Currently, 1.7% of the shares of the stock are sold short.

Institutional Investors Weigh In On BriaCell Therapeutics

A hedge fund recently bought a new stake in BriaCell Therapeutics stock. Vontobel Holding Ltd. acquired a new stake in shares of BriaCell Therapeutics Corp. (NASDAQ:BCTX) during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 80,000 shares of the company’s stock, valued at approximately $99,000. Vontobel Holding Ltd. owned approximately 0.44% of BriaCell Therapeutics at the end of the most recent quarter. Institutional investors own 15.42% of the company’s stock.

Analysts Set New Price Targets

Separately, HC Wainwright reissued a “buy” rating and set a $15.00 price objective on shares of BriaCell Therapeutics in a research note on Thursday, October 3rd.

BriaCell Therapeutics Stock Up 16.6 %

Shares of BCTX stock traded up $0.14 during trading on Friday, hitting $0.98. The company had a trading volume of 1,517,233 shares, compared to its average volume of 1,571,148. The stock’s 50-day moving average is $0.81 and its two-hundred day moving average is $0.93. The stock has a market capitalization of $35.54 million, a price-to-earnings ratio of -0.84 and a beta of 1.39. BriaCell Therapeutics has a 52 week low of $0.46 and a 52 week high of $5.97.

BriaCell Therapeutics (NASDAQ:BCTX) last issued its quarterly earnings results on Monday, October 28th. The company reported ($0.07) EPS for the quarter, topping analysts’ consensus estimates of ($0.52) by $0.45. On average, research analysts predict that BriaCell Therapeutics will post -0.58 EPS for the current fiscal year.

BriaCell Therapeutics Company Profile

BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer.